...
首页> 外文期刊>Cytokine >Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
【24h】

Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells

机译:通过体内调节性T细胞的扩增,低剂量IL-2在慢性GVHD患者中的治疗潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic graft-versus-host disease (cGVHD) is a common complication following allogeneic hematopoietic stem cell transplantation (HSCT), which is characterized by autoimmune like inflammatory responses and reduced levels of regulatory T cells (Tregs). Recently, the use of low-dose IL-2 has been reported to selectively increase Tregs and therefore facilitate immune regulation and promote clinical improvements in cGVHD patients. In this report, we describe the case of a cGVHD patient who was treated with daily low-dose IL-2 therapy. Our observations demonstrate that low-dose IL-2 could induce significant expansion of Tregs in vivo leading to improved Treg/Th17 ratios. The patient showed moderate clinical benefits suggesting that multiple factors may be involved in the immunological responses. Therefore, while the therapeutic potential of low-dose IL-2 is promising, strategic approaches may be needed to induce a clinically significant and sustained Treg effect. (C) 2015 Elsevier Ltd. All rights reserved.
机译:慢性移植物抗宿主病(cGVHD)是同种异体造血干细胞移植(HSCT)后的常见并发症,其特征是自身免疫性如炎症反应和调节性T细胞(Tregs)水平降低。最近,据报道使用低剂量的IL-2可以选择性增加Treg,从而促进cGVHD患者的免疫调节并促进临床改善。在本报告中,我们描述了接受每日低剂量IL-2治疗的cGVHD患者的情况。我们的观察结果表明,低剂量的IL-2可以在体内诱导Treg的显着扩增,从而改善Treg / Th17的比率。该患者显示出中等程度的临床获益,表明免疫反应可能涉及多种因素。因此,尽管低剂量IL-2的治疗潜力是有希望的,但可能需要战略方法来诱导临床上显着且持续的Treg效应。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号